Roquefort Therapeutics (LON:ROQ) Shares Down 2.5% – Here’s What Happened

Roquefort Therapeutics plc (LON:ROQ)’s stock price was down 2.5% on Thursday . The stock traded as low as GBX 0.96 and last traded at GBX 0.98. Approximately 387,197 shares were traded during trading, a decline of 58% from the average daily volume of 927,129 shares. The stock had previously closed at GBX 1.

Roquefort Therapeutics Price Performance

The company has a 50 day moving average price of GBX 1.12 and a 200-day moving average price of GBX 1.51. The company has a quick ratio of 3.07, a current ratio of 2.80 and a debt-to-equity ratio of 8.07. The company has a market cap of £1.60 million, a price-to-earnings ratio of -1.55 and a beta of 0.05.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.